September 04, 2025 a 12:38 pm
ABBV: Analysts Ratings - AbbVie Inc.
AbbVie Inc., a renowned pharmaceutical company, showcases a diverse product lineup addressing various therapeutic areas. The analyst ratings for AbbVie remain predominantly positive, with consistent strong buying interest. This suggests a stable outlook on long-term growth prospects, driven by both innovative product pipelines and strategic collaborations.
Historical Stock Grades
The recent analyst ratings reflect a consensus of sustained positive sentiment towards AbbVie Inc., with a predominance of "Buy" recommendations and no negative indicators such as "Sell" or "Strong Sell".
| Category | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 13 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, the analyst sentiment has shown a slight shift towards neutrality, with "Hold" ratings becoming more frequent. This consistency in recommendation numbers suggests a stable view, with minor adjustments to the "Hold" category.
- There has been a gradual decrease in "Strong Buy" ratings from earlier peaks.
- The total number of ratings has experienced a minor fluctuation, nearly holding steady.
- Most recommendations remain in the "Buy" category, indicating confidence in AbbVie’s strategic direction.
Percentage Trends
The overall percentage distribution of ratings for AbbVie Inc. indicates a steady interest with a predominance in favorable categories. However, the growth in "Hold" ratings highlights an awareness of potential challenges or matured growth prospects.
- The percentage of "Buy" ratings remains dominant but shows slight variability month to month.
- A noticeable consistency is observed in the absence of "Sell" or "Strong Sell" ratings.
- Over the past year, there has been a shift towards "Hold", reflecting a conservative approach driven perhaps by market conditions or company-specific factors.
Latest Analyst Recommendations
Recent analyst activities illustrate continued support from major financial institutions, reflecting confidence in AbbVie's stability and potential for growth.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-01 | Outperform | Outperform | Raymond James |
| 2025-08-01 | Overweight | Overweight | Morgan Stanley |
| 2025-08-01 | Buy | Buy | Guggenheim |
| 2025-05-14 | Neutral | Buy | Citigroup |
| 2025-04-29 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
Analyst recommendations with changes reflect a reevaluation of AbbVie’s market position, potentially due to external factors or shifts in strategic focus.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-14 | Neutral | Buy | Citigroup |
| 2024-11-22 | Outperform | Market Perform | Leerink Partners |
| 2024-11-04 | Buy | Hold | Argus Research |
| 2024-06-05 | Buy | Hold | HSBC |
| 2024-01-29 | Outperform | Market Perform | William Blair |
Interpretation
The current analyst ratings and sentiment indicate a stable outlook for AbbVie Inc. Despite slight shifts towards "Hold" ratings, the overall sentiment remains predominantly positive. The absence of negative recommendations underscores confidence in AbbVie’s business strategy and product pipeline. However, the slight increase in "Hold" ratings could suggest cautious optimism as analysts weigh potential market challenges.
Conclusion
In conclusion, AbbVie Inc. remains a favored stock within the pharmaceutical sector, driven by its robust product offerings and strategic partnerships. Despite minor increases in neutral ratings, the strong "Buy" and "Outperform" sentiments reflect underlying confidence in the company's growth prospects. Investors should consider potential market fluctuations but can find reassurance in AbbVie’s adaptive business strategies and continued innovation.